More Articles Back to Article
New Darzalex formulation approved in EU for subgroup of MM patients
The European Commission granted extended marketing authorization to Johnson & Johnson's Janssen unit for the new formulation of its triple-drug regimen of Darzalex, or daratumumab, combined with with Celgene's Revlimid, or lenalidomide plus dexamethasone, to treat newly diagnosed patients with multiple myeloma who cannot undergo an autologous stem cell transplant. PMLive (UK) (11/20)
Read full article now.
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!